Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Breast Cancer after Radiation Therapy in a Patient with Li-Fraumeni Syndrome: A Case Report

Li-Fraumeni 증후군 환자에서 방사선 치료 후 발생한 유방암: 증례 보고

  • In Na Yoon (Department of Radiology, Ewha Womans University Mokdong Hospital) ;
  • Eun Suk Cha (Department of Radiology, Ewha Womans University Mokdong Hospital) ;
  • Jeoung Hyun Kim (Department of Radiology, Ewha Womans University Mokdong Hospital) ;
  • Jee Eun Lee (Department of Radiology, Ewha Womans University Mokdong Hospital) ;
  • Jin Chung (Department of Radiology, Ewha Womans University Mokdong Hospital)
  • 윤인나 (이화여자대학교 목동병원 영상의학과) ;
  • 차은숙 (이화여자대학교 목동병원 영상의학과) ;
  • 김정현 (이화여자대학교 목동병원 영상의학과) ;
  • 이지은 (이화여자대학교 목동병원 영상의학과) ;
  • 정진 (이화여자대학교 목동병원 영상의학과)
  • Received : 2021.03.19
  • Accepted : 2021.05.02
  • Published : 2022.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Li-Fraumeni syndrome (LFS) is an inherited autosomal-dominant tumor-predisposition disorder caused by germline mutations in the TP53 tumor suppressor gene. Since patients with LFS are likely to develop therapy-related cancers, radiation therapy should be avoided if breast cancer is found in these individuals. Herein, we present a case of secondary breast cancer in an LFS patient after radiation and chemotherapy for the first diagnosed breast sarcoma.

Li-Fraumeni 증후군(이하 LFS)은 TP53 종양 억제 유전자의 생식세포 돌연변이로 인한 상염색체 우성 종양 유발 유전 질환이다. LFS 환자에서는 치료 후 치료와 관련된 암이 발생하기 때문에 LFS 환자에서 발생한 유방암의 치료에 있어 방사선 요법을 피해야 한다. 저자들은 LFS 환자에서 발생한 유방 육종의 방사선 및 화학 요법 치료 후 발생한 유방암 증례를 보고한다.

Keywords

References

  1. Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol 2017;176:539-552 https://doi.org/10.1111/bjh.14461
  2. Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016;122:3673-3681 https://doi.org/10.1002/cncr.30248
  3. Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, et al. Risk of contralateral breast cancer in women with and without pathogenic variants in BRCA1, BRCA2, and tp53 genes in women with very early-onset (< 36 Years) breast cancer. Cancers (Basel) 2020;12:378
  4. Shimatani A, Aono M, Hoshi M, Oebisu N, Iwai T, Takada N, et al. Secondary osteosarcoma in patients previously treated for childhood cancer: three case reports. Mol Clin Oncol 2019;10:153-158
  5. Ji M, Wang L, Shao Y, Cao W, Xu T, Chen S, et al. A novel dysfunctional germline P53 mutation identified in a family with Li-Fraumeni syndrome. Am J Cancer Res 2018;8:165-169
  6. Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012;14:R66
  7. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al, Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010;5:104
  8. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, et al. Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: a hereditary cancer registry study. Cancer Med 2020;9:7954-7963 https://doi.org/10.1002/cam4.3427
  9. Boyle JM, Spreadborough A, Greaves MJ, Birch JM, Varley JM, Scott D. The relationship between radiation-induced G1arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. Br J Cancer 2001;85:293-296 https://doi.org/10.1054/bjoc.2001.1896
  10. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2020;18:380-391 https://doi.org/10.6004/jnccn.2020.0017